<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Help Page</title>
  <style>
    body {
      font-family: sans-serif;
      line-height: 1.6;
      margin: 0;
      padding: 0;
    }

    header, section {
      padding: 2em;
    }

    header {
      background: #333;
      color: white;
      text-align: center;
    }

    section {
      border-bottom: 1px solid #ccc;
    }

    h2 {
      margin-top: 0;
    }

    nav {
      background: #f4f4f4;
      padding: 1em;
      text-align: center;
    }

    nav a {
      margin: 0 1em;
      text-decoration: none;
      color: #333;
    }

    nav a:hover {
      text-decoration: underline;
    }
  </style>
</head>
<body>

  <header>
    <h1>Welcome to the Help Page</h1>
    <p>Select a section below or use a direct link to jump where you need</p>
  </header>

  <nav>
    <a href="#section1">Arterial Plaque Outcome Case Study Outline</a>
    <a href="#section2">Asthma Outcome Case Study Outline</a>
    <a href="#section3">Bronchiectasis Outcome Case Study Outline</a>
    <a href="#section4">Crohn's Outcome Case Study Outline</a>
    <a href="#section5">Cystic Fibrosis Outcome Case Study Outline</a>
    <a href="#section6">Parkinson's Outcome Case Study Outline</a>
    <a href="#section7">Ulcerative Colitis Outcome Case Study Outline</a>
    <!-- <a href="#section8">Section 4</a> -->
  </nav>

  <section id="section1">
    <h2>Arterial Plaque Outcome Case Study Outline</h2>
    <section id="case-study">
      <h2>Outcome Case Study Outline</h2>
      <p><strong>Evaluating the Effect of a Dietary Supplement containing Nattokinase and soluble Stacked Terpenes (Borneol and Trans Cinnamaldehyde) (NBT) on Arterial Plaque Reduction in Adults with Mild to Moderate Atherosclerosis.</strong></p>
    
      <h3>1. Introduction</h3>
      <h4>1.1 Title</h4>
      <p>Study and evaluation of the effectiveness of NBT supplementation in reducing arterial plaque levels and improving vascular health in adults with mild to moderate atherosclerosis.</p>
    
      <h4>1.2 Study Objectives</h4>
      <p><strong>Primary Objective:</strong> To evaluate the effect of oral NBT supplementation in adults with moderate arterial plaque.</p>
      <p><strong>Secondary Objectives:</strong></p>
      <ul>
        <li>Evaluate quality of life improvements.</li>
        <li>Assess tolerability of NBT supplementation.</li>
      </ul>
    
      <h4>1.3 Study Design</h4>
      <p><strong>Type:</strong> Case study</p>
      <p><strong>Duration:</strong> 16 weeks</p>
      <p><strong>Setting:</strong> Outpatient clinics and research centers</p>
      <p><strong>Participants:</strong></p>
      <ul>
        <li>20 Adults aged 40-75 years</li>
        <li>Diagnosed with mild to moderate atherosclerosis based on medical history and imaging</li>
        <li>Willing to comply with the study protocol and provide informed consent</li>
        <li>No major cardiovascular events in the last 6 months</li>
      </ul>
      <p><strong>Exclusion Criteria:</strong></p>
      <ul>
        <li>Severe cardiovascular disease</li>
        <li>Active bleeding disorders or history of major bleeding</li>
        <li>Pregnancy or breastfeeding</li>
        <li>Chronic kidney disease (eGFR &lt; 30)</li>
        <li>Current use of blood thinners or anticoagulants that might interfere with NBT</li>
        <li>History of hypersensitivity to soy products</li>
      </ul>
    
      <h4>1.4 Intervention</h4>
      <p>NBT oral dietary supplement: 1 capsule BID (Twice Daily)</p>
    
      <h4>1.5 Outcome Measures</h4>
      <p><strong>Primary Outcome:</strong></p>
      <ul>
        <li>Reduction in arterial plaque assessed by CIMT or CAC score</li>
        <li>CIMT via high-resolution ultrasound</li>
        <li>CAC via CT scan</li>
      </ul>
      <p><strong>Secondary Outcomes:</strong></p>
      <ul>
        <li><strong>Blood Biomarkers:</strong> Fibrinogen, D-dimer, CRP, Lipid profile, PAI-1, tPA</li>
        <li><strong>Blood Pressure:</strong> Systolic and diastolic changes</li>
        <li><strong>Vascular Function:</strong> Flow-mediated dilation (FMD) of brachial artery</li>
      </ul>
    
      <h4>1.6 Study Timeline</h4>
      <ul>
        <li>Screening and Enrollment: 2 weeks</li>
        <li>Treatment Period: 16 weeks</li>
        <li>Study Start Estimate: November 2025</li>
        <li>Recruitment: September - October 2025</li>
        <li>Intervention: November 2025 - February 2026</li>
        <li>Follow-up: March - April 2026</li>
        <li>Post-intervention Assessments: Week 17</li>
        <li>Optional 6-month follow-up for sustained effects</li>
      </ul>
    
      <h4>1.7 Data Collection and Analysis</h4>
      <p><strong>Data Collection:</strong></p>
      <ul>
        <li>Medical history and demographics</li>
        <li>Baseline and post-intervention measurements: arterial plaque, lipid profile, biomarkers, blood pressure, FMD</li>
      </ul>
      <p><strong>Statistical Analysis:</strong></p>
      <ul>
        <li>Primary: Change in CIMT or CAC using paired t-tests or ANCOVA</li>
        <li>Secondary: Correlation with inflammatory and fibrinolytic markers</li>
        <li>Subgroup: Age, sex, and baseline plaque severity</li>
      </ul>
    
      <h4>1.8 Sample Size Calculation</h4>
      <p>Assess whether there is a moderate effect with NBT (e.g., 10-15% reduction in plaque compared to starting point) in the studied population.</p>
    </section>
    
  </section>

  <section id="section2">
    <section id="case-study-2">
      <h2>Outcome Case Study Outline</h2>
      <p><strong>Evaluating the Effect of a Dietary Supplement containing Nattokinase and soluble Stacked Terpenes (Borneol and Trans Cinnamaldehyde) (NBT) on Arterial Plaque Reduction in Adults with Mild to Moderate Atherosclerosis.</strong></p>
    
      <h3>1. Introduction</h3>
      <h4>1.1 Title</h4>
      <p>Study and evaluation of the effectiveness of NBT supplementation in reducing arterial plaque levels and improving vascular health in adults with mild to moderate atherosclerosis.</p>
    
      <h4>1.2 Study Objectives</h4>
      <p><strong>Primary Objective:</strong> To evaluate the effect of oral NBT supplementation in adults with moderate arterial plaque.</p>
      <p><strong>Secondary Objectives:</strong></p>
      <ul>
        <li>Evaluate quality of life improvements.</li>
        <li>Assess tolerability of NBT supplementation.</li>
      </ul>
    
      <h4>1.3 Study Design</h4>
      <p><strong>Type:</strong> Case study</p>
      <p><strong>Duration:</strong> 16 weeks</p>
      <p><strong>Setting:</strong> Outpatient clinics and research centers</p>
      <p><strong>Participants:</strong></p>
      <ul>
        <li>20 Adults aged 40-75 years</li>
        <li>Diagnosed with mild to moderate atherosclerosis based on medical history and imaging (e.g., carotid ultrasound, CT angiography, or coronary artery calcium score)</li>
        <li>Willing to comply with the study protocol and provide informed consent</li>
        <li>No major cardiovascular events (e.g., myocardial infarction, stroke) in the last 6 months</li>
      </ul>
      <p><strong>Exclusion Criteria:</strong></p>
      <ul>
        <li>Severe cardiovascular disease</li>
        <li>Active bleeding disorders or history of major bleeding</li>
        <li>Pregnancy or breastfeeding</li>
        <li>Chronic kidney disease (eGFR &lt; 30)</li>
        <li>Current use of blood thinners (e.g., warfarin) or other anticoagulants that might interfere with NBT</li>
        <li>History of hypersensitivity to soy products</li>
      </ul>
    
      <h4>1.4 Intervention</h4>
      <p>NBT oral dietary supplement: 1 capsule BID (Twice Daily)</p>
    
      <h4>1.5 Outcome Measures</h4>
      <p><strong>Primary Outcome:</strong></p>
      <ul>
        <li>Reduction in Arterial Plaque as assessed by non-invasive imaging techniques like Carotid Intima-Media Thickness (CIMT) or Coronary Artery Calcium (CAC) Score</li>
        <li>CIMT: measured using high-resolution ultrasound</li>
        <li>CAC: measured using a CT scan to assess calcified plaque</li>
      </ul>
      <p><strong>Secondary Outcomes:</strong></p>
      <ul>
        <li><strong>Blood Biomarkers:</strong> Fibrinogen, D-dimer, CRP, Lipid profile, PAI-1, tPA</li>
        <li><strong>Blood Pressure:</strong> Systolic and diastolic measurements pre- and post-intervention</li>
        <li><strong>Vascular Function:</strong> Flow-mediated dilation (FMD) of the brachial artery</li>
      </ul>
    
      <h4>1.6 Study Timeline</h4>
      <ul>
        <li>Screening and Enrollment: 2 weeks</li>
        <li>Treatment Period: 16 weeks</li>
        <li>Study Start Estimate: November 2025</li>
        <li>Recruitment Period: September - October 2025</li>
        <li>Intervention Period: November 2025 - February 2026</li>
        <li>Follow-up and Analysis: March - April 2026</li>
        <li>Post-intervention Assessments: Week 17</li>
        <li>Optional follow-up at 6 months to assess sustained effects</li>
      </ul>
    
      <h4>1.7 Data Collection and Analysis</h4>
      <p><strong>Data Collection:</strong></p>
      <ul>
        <li>Medical history and demographics at baseline</li>
        <li>Baseline and post-intervention measurements: arterial plaque (CIMT or CAC), lipid profile, biomarkers, blood pressure, FMD</li>
      </ul>
      <p><strong>Statistical Analysis:</strong></p>
      <ul>
        <li>Primary analysis: Change in CIMT or CAC score from baseline to post-treatment (12 weeks) using paired t-tests or ANCOVA adjusted for baseline values</li>
        <li>Secondary analysis: Correlation between plaque reduction and changes in inflammatory/fibrinolytic markers (e.g., fibrinogen, CRP, PAI-1)</li>
        <li>Subgroup analysis: Differences by age, sex, or baseline plaque severity</li>
      </ul>
    
      <h4>1.8 Sample Size Calculation</h4>
      <p>Assess whether there is a moderate effect with NBT (e.g., 10–15% reduction in plaque compared to starting point) in the population studied.</p>
    </section>
    
  </section>

  <section id="section3">
    <section id="case-study-3">
      <h2>Case Study Outline</h2>
      <p><strong>Evaluating the Effect of a Dietary Supplement on Pulmonary Function in Children with Bronchiectasis</strong></p>
    
      <h3>1. Introduction</h3>
      <h4>1.1 Background Information</h4>
      <p>Bronchiectasis (BRO) can be a genetic or acquired disorder that affects the lungs, pancreas, and other organs. Children with BRO often experience chronic pulmonary function and respiratory problems.</p>
    
      <h4>1.2 Objective of the Case Study</h4>
      <p>To evaluate the impact of Soluble Isolate Extracts of botanical terpenes and oils (BTO) on mucus production, respiratory function, and overall pulmonary response in 20 children diagnosed with Bronchiectasis over a 4-week period.</p>
    
      <h3>2. Study Design</h3>
    
      <h4>2.1 Study Population</h4>
      <ul>
        <li><strong>Sample Size:</strong> 20 children with BRO</li>
        <li><strong>Age Range:</strong> 8–14 years old</li>
        <li><strong>Inclusion Criteria:</strong>
          <ul>
            <li>Diagnosis of BRO from Cystic Fibrosis confirmed by genetic testing or sweat chloride test, or Primary Ciliary Dyskinesia (PCD)</li>
            <li>Stable clinical condition (no acute exacerbations or hospitalizations within the last 30 days)</li>
          </ul>
        </li>
        <li><strong>Exclusion Criteria:</strong>
          <ul>
            <li>Severe complications (e.g., liver failure, severe gastrointestinal disorders)</li>
            <li>Allergies or intolerances to the supplement ingredients</li>
          </ul>
        </li>
      </ul>
    
      <h4>2.2 Intervention</h4>
      <p><strong>Supplementation Protocol:</strong></p>
      <ul>
        <li><strong>Supplement Type:</strong> Oral dietary supplement containing Soluble Isolate Extracts of botanical terpenes and oils (BTO)</li>
        <li><strong>Duration:</strong> 4 weeks</li>
        <li><strong>Administration:</strong> 2 capsules twice daily</li>
        <li>Participants will continue standard nutritional management advised by their healthcare providers.</li>
      </ul>
    
      <h4>2.3 Outcome Measures</h4>
      <ul>
        <li><strong>Primary Outcome:</strong>
          <ul>
            <li>Pulmonary function: Spirometry (FEV1 and FVC)</li>
            <li>Clinical symptoms: Cough, wheezing, sputum production — recorded in daily logs</li>
          </ul>
        </li>
      </ul>
    
      <h3>3. Baseline Data</h3>
      <h4>3.1 Participant Demographics</h4>
      <p>20 children, ages 8–14 years</p>
    
      <h4>3.2 Clinical Characteristics</h4>
      <p>Pulmonary Function (FEV1): Mean of 80% predicted value (mild-to-moderate impairment)</p>
    
      <h3>4. Nutritional Counseling</h3>
      <p>All participants will continue their regular BRO-specific nutritional treatment.</p>
    
      <h3>5. Monitoring and Data Collection</h3>
      <ul>
        <li><strong>Follow-Up Measurements:</strong> Daily and weekly</li>
        <li>Weight, height, and BMI tracking</li>
        <li>Weekly spirometry to monitor FEV1 and FVC</li>
        <li>Parents will track symptoms daily (e.g., coughing, sputum production, respiratory distress)</li>
      </ul>
    
      <h3>6. Clinical Symptoms / Case Observations</h3>
      <p>Evaluate reduction in respiratory symptoms such as coughing and wheezing based on parent reports and weekly check-ins.</p>
    
      <h3>7. Data Collection Timeline</h3>
      <ul>
        <li><strong>Week 0 (Pre-treatment):</strong> Baseline measurements (FEV1, mucus production, asthma control, quality of life)</li>
        <li><strong>Week 2 (Mid-treatment):</strong> Follow-up for preliminary results</li>
        <li><strong>Week 4 (Post-treatment):</strong> Final measurements and analysis</li>
        <li><strong>Follow-up (Optional):</strong> 1-month post-treatment assessment for lasting effects</li>
      </ul>
    
      <h3>8. Ethical Considerations</h3>
      <ul>
        <li><strong>Informed Consent:</strong> Written consent will be obtained from all participants (via guardians)</li>
        <li><strong>Data Privacy:</strong> All data will be kept confidential and presented in aggregate form</li>
      </ul>
    
      <h3>9. Study Timeline</h3>
      <ul>
        <li><strong>Screening and Enrollment:</strong> 2 weeks</li>
        <li><strong>Treatment Period:</strong> 4 weeks</li>
        <li><strong>Study Start Estimate:</strong> November 2025</li>
        <li><strong>Recruitment Period:</strong> September–October 2025</li>
        <li><strong>Intervention Period:</strong> November 2025 – January 2026</li>
        <li><strong>Follow-up and Analysis:</strong> February 2026</li>
      </ul>
    
      <h3>10. Conclusion</h3>
      <p>This study will assess the effect of soluble botanical terpenes and oils (BTO) on mucus production, respiratory function, and overall pulmonary response in children with Bronchiectasis.</p>
    
      <h4>Interpretation of Results</h4>
      <p>Determine whether improvements in FEV1 and FVC reflect clinically significant changes in lung capacity.</p>
    </section>
    
  </section>

  <section id="section4">
    Version 2.
    Outcome Case Study Outline: Evaluating the Effect of Butyrate Supplementation on Symptoms of Crohn’s Disease
    
    1. Title
    Study and Evaluation of Micro Dose, soluble, sustained release, Butyrate Supplementation to Observe Clinical Outcomes in adults with Crohn's Disease
    
    2. Study Objectives
    Primary Objective: To evaluate the effect of micro dose oral butyrate supplementation in adults with moderate Crohn's disease over 4 weeks.
    Secondary Objectives:
    Evaluate quality of life improvements.
    Assess tolerability of butyrate supplementation.
    
    3. Study Design
    Type: Case study.
    Duration: 4 weeks.
    Setting: Outpatient clinics and research centers.
    Participants: 20 adults aged 18-65 years with a confirmed diagnosis of moderate Crohn's disease (based on the Crohn's Disease Activity Index, CDAI 150–450).
    
    4. Inclusion Criteria
    Age 18-65 years.
    Diagnosis of moderate Crohn's disease with disease activity score (CDAI) of 150-450.
    Signed informed consent.
    5. Exclusion Criteria
    Severe Crohn's disease (CDAI >450) or active complications (e.g., fistulas, strictures).
    Recent use of biologic therapies or systemic corticosteroids within 4 weeks.
    History of significant gastrointestinal surgery (except appendectomy).
    Pregnancy, breastfeeding, or plans to become pregnant during the study.
    Known allergies to butyrate or components of the supplement.
    
    6. Intervention
    Butyrate Supplementation Protocol:
    Supplement Type: Oral micro dose, soluble, individual molecule butyrate supplementation, in sustained release capsules.  
    Exclusion of less effective forms of butyrate: Sodium or Calcium butyrate or butyrate tributyrin (triglyceride form)
     Duration of Treatment: 4 weeks.
    Administration: Oral supplementation 5 capsules twice daily.
    
    
    7. Outcome Measures
    Primary Outcome:
    Disease Activity: Evaluate any change in Crohn's Disease Activity Index (CDAI) from baseline to 4 weeks.
    Secondary Outcomes:
    Quality of Life: Measured using the Inflammatory Bowel Disease Questionnaire (IBDQ) to assess changes in physical, social, and emotional well-being.
    
    
    8. Considerations
    Informed Consent: Written informed consent will be obtained from all participants before enrollment.
    Data Privacy: All participant data will be kept confidential, and results will be reported in aggregate form to ensure participant privacy.
    
    9. Timeline
    Screening and Enrollment: 2 weeks
    Treatment Period: 4 weeks
    Study Start estimate: November 2025.
    Recruitment Period: September -October 2025.
    Intervention Period: November 2025 - January 2026.
    Follow-up and Analysis: February 2026.
    
    10. Conclusion
    This study will assess the effect of soluble, micro dose butyrate supplementation in evaluating symptoms of Crohn's disease, focusing on disease activity, inflammation, quality of life, and gut microbiota changes. If proven effective, butyrate could offer a natural, adjunctive means to support Crohn's disease adults, with minimal side effects.
    
    
    
  </section>
  <section id="section5">
    <section id="case-study-5">
      <h2>Case Study Outline</h2>
      <p><strong>Evaluating the Effect of a Dietary Supplement on Pulmonary Function in Children with Cystic Fibrosis</strong></p>
    
      <h3>1. Introduction</h3>
      <ul>
        <li><strong>Background Information:</strong> Cystic Fibrosis (CF) is a genetic disorder affecting the lungs, pancreas, and other organs. Children with CF often experience chronic pulmonary and respiratory problems.</li>
        <li><strong>Objective:</strong> To evaluate the impact of Soluble Isolate Extracts of botanical terpenes and oils (BTO) on pulmonary function in 20 children diagnosed with CF over a 4-week period.</li>
      </ul>
    
      <h3>2. Study Design</h3>
      <h4>2.1. Study Population:</h4>
      <ul>
        <li><strong>Sample Size:</strong> 20 children with CF</li>
        <li><strong>Age Range:</strong> 8–14 years</li>
        <li><strong>Inclusion Criteria:</strong>
          <ul>
            <li>Diagnosis of CF confirmed by genetic testing or sweat chloride test</li>
            <li>Stable clinical condition (no acute exacerbations or hospitalizations within the last 30 days)</li>
          </ul>
        </li>
        <li><strong>Exclusion Criteria:</strong>
          <ul>
            <li>Severe CF-related complications (e.g., liver failure, severe GI disorders)</li>
            <li>Allergies or intolerances to supplement ingredients</li>
          </ul>
        </li>
      </ul>
    
      <h4>2.2. Intervention:</h4>
      <ul>
        <li><strong>Supplement Type:</strong> Oral dietary supplement of Soluble Isolate Extracts of botanical terpenes and oils (BTO)</li>
        <li><strong>Duration:</strong> 4 weeks</li>
        <li><strong>Administration:</strong> 2 capsules, twice daily</li>
        <li>Participants will continue standard nutritional care as advised by healthcare providers</li>
      </ul>
    
      <h4>2.3. Outcome Measures:</h4>
      <ul>
        <li><strong>Primary Outcome:</strong>
          <ul>
            <li>Pulmonary Function via spirometry: FEV1 and FVC</li>
            <li>Clinical Symptoms: Cough, wheezing, sputum production (logged daily)</li>
          </ul>
        </li>
      </ul>
    
      <h3>3. Baseline Data</h3>
      <h4>3.1. Participant Demographics:</h4>
      <ul>
        <li>20 children aged 8–14 years</li>
      </ul>
      <h4>3.2. Clinical Characteristics:</h4>
      <ul>
        <li>FEV1 mean value at baseline: 80% of predicted (mild-to-moderate impairment)</li>
      </ul>
    
      <h3>4. Nutritional Counseling</h3>
      <p>All participants will continue their regular CF nutrition regimen throughout the study.</p>
    
      <h3>5. Monitoring and Data Collection</h3>
      <ul>
        <li>Weight, height, and BMI will be recorded weekly</li>
        <li>Spirometry (FEV1, FVC) will be conducted weekly</li>
        <li>Daily symptom diaries maintained by parents: coughing, sputum, respiratory distress</li>
      </ul>
    
      <h3>6. Clinical Symptoms</h3>
      <p>Monitor symptom frequency, with a focus on reduction in coughing and wheezing.</p>
    
      <h3>7. Data Collection Timeline</h3>
      <ul>
        <li><strong>Week 0 (Pre-treatment):</strong> Baseline FEV1, mucus, asthma control, quality of life</li>
        <li><strong>Week 2 (Mid-treatment):</strong> Follow-up assessment</li>
        <li><strong>Week 4 (Post-treatment):</strong> Final data collection</li>
        <li><strong>Optional Follow-up:</strong> 1-month post-treatment for lasting effects</li>
      </ul>
    
      <h3>8. Considerations</h3>
      <ul>
        <li><strong>Informed Consent:</strong> Required from all participants before enrollment</li>
        <li><strong>Data Privacy:</strong> All data anonymized and reported in aggregate form</li>
      </ul>
    
      <h3>9. Timeline</h3>
      <ul>
        <li><strong>Screening and Enrollment:</strong> 2 weeks</li>
        <li><strong>Treatment Period:</strong> 4 weeks</li>
        <li><strong>Estimated Study Start:</strong> November 2025</li>
        <li><strong>Recruitment Period:</strong> September–October 2025</li>
        <li><strong>Intervention Period:</strong> November 2025 – January 2026</li>
        <li><strong>Follow-up and Analysis:</strong> February 2026</li>
      </ul>
    
      <h3>10. Conclusion</h3>
      <p>This study will assess the effect of soluble botanical terpenes and oils (BTO) on mucus production, pulmonary function, and overall respiratory health in children with CF.</p>
    
      <h4>Interpretation of Results:</h4>
      <p>Evaluate clinical significance of improvements in FEV1 and FVC as indicators of enhanced lung capacity.</p>
    </section>
    
  </section>
  <section id="section6">
    <section id="case-study-6">
      <h2>Case Study Outline</h2>
      <p><strong>Evaluating the Effect of Micro Dose, Soluble Butyrate and Soluble Glutathione Supplementation on Parkinson’s Disease and Parkinsonism</strong></p>
    
      <h3>1. Introduction</h3>
      <p><strong>Title:</strong> Study and Evaluation of Micro Dose, Soluble, Sustained Release Butyrate and Glutathione (SB-SG) Supplementation to Observe Clinical Outcomes in Adults with Parkinson’s Disease</p>
    
      <h3>2. Study Objectives</h3>
      <ul>
        <li><strong>Primary Objective:</strong> Evaluate the effect of SB-SG supplementation in adults with Parkinson’s Disease and Parkinsonism over 4 weeks.</li>
        <li><strong>Secondary Objectives:</strong>
          <ul>
            <li>Assess improvements in quality of life.</li>
            <li>Evaluate tolerability of both supplements.</li>
          </ul>
        </li>
      </ul>
    
      <h3>3. Study Design</h3>
      <ul>
        <li><strong>Type:</strong> Case study</li>
        <li><strong>Duration:</strong> 4 weeks</li>
        <li><strong>Setting:</strong> Outpatient clinics and research centers</li>
        <li><strong>Participants:</strong> 20 adults with confirmed diagnosis of Parkinson’s Disease or Parkinsonism</li>
        <li><strong>Subject Criteria:</strong> Elderly subjects with mild to moderate Parkinson’s Disease or Parkinsonism</li>
        <li><strong>Screening Protocol:</strong>
          <ul>
            <li>Clinical Screening for: Bradykinesia, Cog-Wheeling, Pill-Rolling, Masked Facies, Festinating Gait, and Retropulsion</li>
          </ul>
        </li>
      </ul>
    
      <h3>4. Supplementation Protocol</h3>
      <ul>
        <li><strong>Supplement Type:</strong> Oral dose SB-SG</li>
        <li><strong>Excluded Forms:</strong> Sodium or Calcium butyrate, and tributyrin (triglyceride form)</li>
        <li><strong>Duration:</strong> 4 weeks</li>
        <li><strong>Administration:</strong>
          <ul>
            <li><strong>Butyrate:</strong> 5 capsules BID (twice daily) for Week 1, then reduce to 3 capsules BID. If regression occurs, return to original dose.</li>
            <li><strong>Glutathione:</strong> 3 capsules BID for Week 1, then reduce to 2 capsules BID. If regression occurs, return to original dose.</li>
            <li><strong>Restrictions:</strong> No alcohol or acetaminophen during treatment period</li>
          </ul>
        </li>
      </ul>
    
      <h3>5. Diet Protocol</h3>
      <ul>
        <li>Eliminate calcium propionate and propionic acid (e.g., from preserved breads, chips, etc.)</li>
        <li>Eliminate most dietary soluble fiber for 3 weeks</li>
        <li>Encourage consumption of insoluble fiber during the same period</li>
        <li>Subjects will log their daily diet throughout the study</li>
        <li><strong>Day 30 Endpoint:</strong> Repeat Parkinson’s Clinical Screening and Parkinson’s Questionnaire</li>
      </ul>
    
      <h3>6. Considerations</h3>
      <ul>
        <li><strong>Informed Consent:</strong> Required from all participants before enrollment</li>
        <li><strong>Data Privacy:</strong> Participant data will be anonymized and reported in aggregate</li>
      </ul>
    
      <h3>7. Timeline</h3>
      <ul>
        <li><strong>Screening and Enrollment:</strong> 2 weeks</li>
        <li><strong>Treatment Period:</strong> 4 weeks</li>
        <li><strong>Estimated Study Start:</strong> November 2025</li>
        <li><strong>Recruitment Period:</strong> September–October 2025</li>
        <li><strong>Intervention Period:</strong> November 2025 – January 2026</li>
        <li><strong>Follow-up and Analysis:</strong> February 2026</li>
      </ul>
    </section>
    
  </section>
  <section id="section7">
    <section id="case-study-7">
      <h2>Case Study Outline</h2>
      <p><strong>Evaluating the Effect of Butyrate Supplementation on Symptoms of Ulcerative Colitis (UC)</strong></p>
    
      <h3>1. Introduction</h3>
      <p><strong>Title:</strong> Study and Evaluation of Micro Dose, Soluble, Sustained Release Butyrate Supplementation to Observe Clinical Outcomes in Adults with Ulcerative Colitis Disease</p>
    
      <h3>2. Study Objectives</h3>
      <ul>
        <li><strong>Primary Objective:</strong> Evaluate the effect of micro dose oral butyrate supplementation in adults with moderate Ulcerative Colitis over 4 weeks.</li>
        <li><strong>Secondary Objectives:</strong>
          <ul>
            <li>Assess quality of life improvements.</li>
            <li>Evaluate tolerability of butyrate supplementation.</li>
          </ul>
        </li>
      </ul>
    
      <h3>3. Study Design</h3>
      <ul>
        <li><strong>Type:</strong> Case study</li>
        <li><strong>Duration:</strong> 4 weeks</li>
        <li><strong>Setting:</strong> Outpatient clinics and research centers</li>
        <li><strong>Participants:</strong> 20 adults aged 18–65 with a confirmed diagnosis of moderate Ulcerative Colitis</li>
        <li><strong>Diagnosis Criteria:</strong>
          <ul>
            <li>Disease Activity Index (DAI): Score of 14 (scale 0–20)</li>
            <li>Elevated CRP: ≥10 mg/L</li>
            <li>Stool Frequency: 3–7 per day</li>
            <li>QoL: Moderately impaired (IBDQ)</li>
          </ul>
        </li>
      </ul>
    
      <h3>4. Inclusion Criteria</h3>
      <ul>
        <li>Aged 18–65</li>
        <li>Confirmed moderate UC diagnosis</li>
        <li>Elevated CRP and DAI score of 14</li>
        <li>Moderately impaired QoL (IBDQ)</li>
        <li>Stool frequency 3–7 times/day</li>
        <li>Signed informed consent</li>
      </ul>
    
      <h3>5. Intervention</h3>
      <ul>
        <li><strong>Supplement Type:</strong> Oral micro dose, soluble, individual molecule butyrate in sustained release capsules</li>
        <li><strong>Excluded Forms:</strong> Sodium/calcium butyrate and tributyrin (triglyceride form)</li>
        <li><strong>Duration:</strong> 4 weeks</li>
        <li><strong>Administration:</strong> 5 capsules twice daily</li>
      </ul>
    
      <h3>5.2. Exclusion Criteria</h3>
      <ul>
        <li>Severe UC or active complications (fistulas, strictures)</li>
        <li>Use of biologics or corticosteroids within 4 weeks</li>
        <li>History of major GI surgery (except appendectomy)</li>
        <li>Pregnancy, breastfeeding, or plans to become pregnant</li>
        <li>Known allergy to butyrate or supplement components</li>
      </ul>
    
      <h3>6. Supplementation Group</h3>
      <ul>
        <li>Investigation group will receive the specified butyrate formulation described above</li>
      </ul>
    
      <h3>7. Outcome Measures</h3>
      <ul>
        <li><strong>Primary Outcome:</strong> Disease Activity Index (DAI) changes in stool frequency, abdominal pain, and blood in stools</li>
        <li><strong>Secondary Outcomes:</strong>
          <ul>
            <li>CRP and fecal calprotectin levels</li>
            <li>IBDQ scores pre- and post-study</li>
            <li>Self-reported symptoms: diarrhea, bloating, and discomfort</li>
          </ul>
        </li>
      </ul>
    
      <h3>8. Considerations</h3>
      <ul>
        <li><strong>Informed Consent:</strong> Required from all participants</li>
        <li><strong>Data Privacy:</strong> Anonymized and reported in aggregate</li>
      </ul>
    
      <h3>9. Timeline</h3>
      <ul>
        <li><strong>Screening and Enrollment:</strong> 2 weeks</li>
        <li><strong>Treatment Period:</strong> 4 weeks</li>
        <li><strong>Study Start Estimate:</strong> November 2025</li>
        <li><strong>Recruitment Period:</strong> September–October 2025</li>
        <li><strong>Intervention Period:</strong> November 2025 – January 2026</li>
        <li><strong>Follow-up and Analysis:</strong> February 2026</li>
      </ul>
    
      <h3>10. Conclusion</h3>
      <p>This study will assess the effect of soluble, micro dose butyrate supplementation on Ulcerative Colitis symptoms, disease activity, inflammation, and quality of life. If effective, butyrate may offer a safe, natural adjunctive therapy with minimal side effects.</p>
    </section>
    
  </section>
  <!-- <section id="section8">
    <h2>Section 4: Billing and Payments</h2>
    <p>Answers to common billing questions and how to manage your account.</p>
  </section>
  <section id="section9">
    <h2>Section 4: Billing and Payments</h2>
    <p>Answers to common billing questions and how to manage your account.</p>
  </section> -->

</body>
</html>

